Meridian Bioscience Inc. (NASDAQ:VIVO) declared a quarterly dividend on Wednesday, November 8th, NASDAQ reports. Shareholders of record on Monday, November 20th will be given a dividend of 0.125 per share on Thursday, November 30th. This represents a $0.50 annualized dividend and a yield of 3.44%. The ex-dividend date of this dividend is Friday, November 17th.
Meridian Bioscience (NASDAQ:VIVO) opened at $14.55 on Friday. The company has a quick ratio of 4.42, a current ratio of 6.47 and a debt-to-equity ratio of 0.31. Meridian Bioscience has a 1-year low of $10.75 and a 1-year high of $18.58. The stock has a market cap of $614.05, a price-to-earnings ratio of 21.40 and a beta of 0.89.
Meridian Bioscience (NASDAQ:VIVO) last released its quarterly earnings results on Thursday, November 9th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.15. Meridian Bioscience had a net margin of 10.74% and a return on equity of 17.07%. The business had revenue of $49.70 million for the quarter, compared to analyst estimates of $48.28 million. During the same period in the previous year, the company earned $0.14 earnings per share. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. sell-side analysts anticipate that Meridian Bioscience will post 0.66 EPS for the current fiscal year.
In related news, Chairman John A. Kraeutler acquired 7,000 shares of the stock in a transaction dated Thursday, August 24th. The stock was acquired at an average cost of $13.67 per share, for a total transaction of $95,690.00. Following the completion of the purchase, the chairman now owns 345,230 shares of the company’s stock, valued at approximately $4,719,294.10. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 2.30% of the company’s stock.
Several equities analysts have issued reports on the stock. Canaccord Genuity reaffirmed a “hold” rating and issued a $14.00 price target on shares of Meridian Bioscience in a report on Friday, October 13th. Zacks Investment Research upgraded shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, October 5th. Finally, BidaskClub downgraded shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Three equities research analysts have rated the stock with a sell rating and three have given a hold rating to the stock. Meridian Bioscience has an average rating of “Hold” and a consensus target price of $14.00.
WARNING: This story was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/11/12/meridian-bioscience-inc-vivo-plans-0-13-quarterly-dividend.html.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.